Literature DB >> 12450320

Role of ketoconazole treatment in urinary-free cortisol-to-cortisone and tetrahydrocortisol-to-tetrahydrocortisone ratios in nonectopic Cushing's syndrome.

Pablo Stiefel1, José S García-Morillo, Luis Jimenez, Encarnación Pamies, María Luisa Miranda, Joaquín Carneado, José Villar, Alfonso Leal-Cerro.   

Abstract

We hypothesized that in nonectopic Cushing syndrome there is an insufficient activity of type II (renal) 11beta-hydroxysteroid dehydrogenase (11beta-HSD2) that is related to cortisol excess, rather than to corticotropin (adrenocorticotropic hormone [ACTH]) levels. We measured plasma ACTH and urinary-free cortisol (UFF), urinary-free cortisone (UFE), tetrahydrocortisol (UTHF), and tetrahydrocortisone (UTHE) in 24-h urine samples of 24 healthy subjects and 15 patients diagnosed with nonectopic Cushing syndrome. Then, in the group of patients, a new 24-h urine sample was collected after treatment with 800 mg daily of ketoconazole. The UFF/UFE and UTHF/UTHE ratios were calculated as an estimation of 11beta-HSD2 activity. The patients had an increase in both the UFF/UFE (19.95 +/- 10.3 vs 5.78 +/- 4.72 nmol/24 h; p < 0.0001) and UTHF/UTHE ratios (5.36 +/- 5.23 vs 1.39 +/- 0.95 nmol/24 h; p < 0.001). Both UFF/UFE and UTHF/UTHE ratios decreased after ketoconazole treatment (19.95 +/- 10.3 vs 12.2 +/- 6.9 nmol/24 h; p < 0.005; and 5.36 +/- 5.23 vs 1.62 vs 1.21 nmol/24 h; p < 0.001, respectively). The control subjects had a significant relationship between UFF and UFE (r = 0.70, p < 0.0001), and between UTHF and UTHE (r = 0.75, p < 0.0001) that did not exist in the patient group. After ketoconazole treatment, the decrease in cortisol excretion in the patient group allowed a positive and significant relation between UFF and UFE (r = 0.64, p < 0.01) and between UTHF and UTHE (r = 0.56, p < 0.05) to appear. There was not any significant relationship between either UFF/UFE or UTHF/UTHE ratios and plasma levels of ACTH.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12450320     DOI: 10.1385/ENDO:18:3:279

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  21 in total

1.  Cloning of human mineralocorticoid receptor complementary DNA: structural and functional kinship with the glucocorticoid receptor.

Authors:  J L Arriza; C Weinberger; G Cerelli; T M Glaser; B L Handelin; D E Housman; R M Evans
Journal:  Science       Date:  1987-07-17       Impact factor: 47.728

Review 2.  The use of ketoconazole as an inhibitor of steroid production.

Authors:  N Sonino
Journal:  N Engl J Med       Date:  1987-09-24       Impact factor: 91.245

3.  11beta-hydroxysteroid dehydrogenase and corticosteroid action in lyon hypertensive rats.

Authors:  S A Lloyd-MacGilp; S M Nelson; M Florin; M Lo; J McKinnell; J Sassard; C J Kenyon
Journal:  Hypertension       Date:  1999-11       Impact factor: 10.190

4.  Urinary free cortisone and the assessment of 11 beta-hydroxysteroid dehydrogenase activity in man.

Authors:  M Palermo; C H Shackleton; F Mantero; P M Stewart
Journal:  Clin Endocrinol (Oxf)       Date:  1996-11       Impact factor: 3.478

5.  Activation of 11 beta-hydroxysteroid dehydrogenase by dehydroepiandrosterone sulphate as an anti-hypertensive agent in spontaneously hypertensive rats.

Authors:  M Homma; T Onodera; M Hirabatake; K Oka; M Kanazawa; T Miwa; T Hayashi
Journal:  J Pharm Pharmacol       Date:  1998-10       Impact factor: 3.765

6.  Mineralocorticoid excess and inhibition of 11 beta-hydroxysteroid dehydrogenase in patients with ectopic ACTH syndrome.

Authors:  B R Walker; J C Campbell; R Fraser; P M Stewart; C R Edwards
Journal:  Clin Endocrinol (Oxf)       Date:  1992-12       Impact factor: 3.478

7.  Placental 11 beta-hydroxysteroid dehydrogenase activity in normotensive and pre-eclamptic pregnancies.

Authors:  C O McCalla; V L Nacharaju; O Muneyyirci-Delale; S Glasgow; J G Feldman
Journal:  Steroids       Date:  1998-10       Impact factor: 2.668

8.  Evidence of coexisting changes in 11 beta-hydroxysteroid dehydrogenase and 5 beta-reductase activity in subjects with untreated essential hypertension.

Authors:  A Soro; M C Ingram; G Tonolo; N Glorioso; R Fraser
Journal:  Hypertension       Date:  1995-01       Impact factor: 10.190

9.  Regulation of the 11 beta-hydroxysteroid dehydrogenase in the rat adrenal. Decrease enzymatic activity induced by ACTH.

Authors:  H Morita; E N Cozza; M Y Zhou; E P Gomez-Sanchez; D G Romero; C E Gomez-Sanchez
Journal:  Endocrine       Date:  1997-12       Impact factor: 3.633

10.  Deficient inactivation of cortisol by 11 beta-hydroxysteroid dehydrogenase in essential hypertension.

Authors:  B R Walker; P M Stewart; C H Shackleton; P L Padfield; C R Edwards
Journal:  Clin Endocrinol (Oxf)       Date:  1993-08       Impact factor: 3.478

View more
  3 in total

1.  Accuracy of immunoassay and mass spectrometry urinary free cortisol in the diagnosis of Cushing's syndrome.

Authors:  G Aranda; M Careaga; F A Hanzu; I Patrascioiu; P Ríos; M Mora; B Morales-Romero; W Jiménez; I Halperin; G Casals
Journal:  Pituitary       Date:  2016-10       Impact factor: 4.107

2.  Role of the Renin-Angiotensin system and aldosterone on cardiometabolic syndrome.

Authors:  P Stiefel; A J Vallejo-Vaz; S García Morillo; J Villar
Journal:  Int J Hypertens       Date:  2011-06-23       Impact factor: 2.420

Review 3.  Effectiveness of medical treatment for Cushing's syndrome: a systematic review and meta-analysis.

Authors:  Leonie H A Broersen; Meghna Jha; Nienke R Biermasz; Alberto M Pereira; Olaf M Dekkers
Journal:  Pituitary       Date:  2018-12       Impact factor: 4.107

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.